After 19 years of survivorship, one cancer survivor reflects on life's changing seasons, managing scan anxiety and finding support beyond treatment.
|Articles|January 5, 2021
Kidney Cancer News and Updates That Patients May Have Missed in 2020
Author(s)CURE staff
A roundup of some kidney cancer news and updates that occurred in 2020 that patients may have missed.
Advertisement
There were several updates in the field of kidney cancer in 2020. Here, CURE® looks back at some of the news and updates in the field that patients may have missed.
- At five years of follow-up, treatment with Opdivo (nivolumab) demonstrated superior overall survival and objective response rates, compared with Afinitor (everolimus), in patients with previously treated advanced or metastatic renal cell carcinoma (RCC), according to results from the phase 3 Checkmate-025 study.
READ MORE . - Patients with advanced, previously untreated RCC may soon have a new option in the novel combination of Opdivo (nivolumab) and Cabometyx (cabozantinib), according to phase 3 results of the CheckMate-9ER trial.
READ MORE .
- Birth weight, height and childhood body mass index (BMI) are associated with adult RCC, meaning they could be valuable predictors for a person’s risk of disease, according to new findings published in the European Journal of Epidemiology.
READ MORE . - Data presented at the 2020 ASCO Virtual Scientific Program demonstrated that treatment with savolitinib showed encouraging efficacy and an improved safety data over standard-of-care Sutent (sunitinib) in patients with MET-driven papillary RCC.
READ MORE . - Treatment with Cabometyx (cabozantinib) in combination with Tecentriq (atezolizumab) demonstrated promising clinical activity in patients with advanced clear cell RCC, according to data presented at the 2020 ESMO Virtual Congress.
READ MORE . - Data from a phase 2 study presented during the 2020 ASCO Virtual Scientific Program demonstrated that Avastin (bevacizumab) in combination with Tarceva (erlotinib) was well tolerated and produced encouraging clinical outcomes in patients with advanced hereditary leiomyomatosis and RCC or sporadic papillary RCC.
READ MORE . - Fotivda (tivozanib) significantly improved survival, compared with Nexavar (sorafenib), in patients with highly relapsed or refractory metastatic RCC, according to results from the phase 3 TIVO-3 trial presented at the 2020 ASCO Virtual Scientific Program.
READ MORE .
For more news on cancer updates, research and education, don’t forget to
Advertisement
Related to this article
Psychiatrist Dr. Yesne Alici of Memorial Sloan Kettering Cancer Center answers questions about family relationships during cancer, from asking for help to talking with children and friends.
Among more than 12,000 cancer survivors 65 and older, those who stayed physically active after diagnosis tended to have lower health care costs, an American Cancer Society study published Oct. 21, 2026, in CANCER found.
The FDA grants traditional approval to Keytruda and Keytruda Qlex for TMB-H solid tumors, updating the threshold to at least 13 mutations per megabase.
Martha Carlson reflects on her 11 years with metastatic breast cancer and explores how resilience, purpose and the stories we tell ourselves shape the cancer experience.
A study found that 1 in 9 older cancer survivors developed a second cancer, highlighting why routine screening remains important beyond five years.
After breast cancer at 30, Aisha shares her journey through motherhood, a double mastectomy, body image struggles and the challenges of survivorship.
Learn why hepatitis B can reactivate during cancer treatment, which therapies increase the risk and how antiviral medicines can help protect liver health.
Advertisement
Advertisement
Trending on CURE
1
FDA Grants Traditional Approval to Keytruda for TMB-H Solid Tumors
2
Why Cancer Screening Remains Important for Long-Term Cancer Survivors
3
FDA Clears AI Tool Using MRI to Gauge Breast Cancer Recurrence
4
Psychiatrist Answers Questions About Family and Relationships During Cancer
5